Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 126 results for thyroid* OR hypothyroid* OR Hyperthyroid* OR goiter

  1. Lithium Support Service provided by community pharmacists

    patient is having their lithium levels monitored every three months and their thyroid function and renal function monitored every six...

  2. The Impact of Introducing a Lithium Care Pathway

    documentation of discussion of side effects (36% to 100%); kidney risk (0% to 95%); thyroid risk (0% to 95%) and toxicity risk (16% to...

  3. YOURmeds for medication support in long-term conditions (MIB289)

    NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .

  4. Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions (MIB15)

    NICE has developed a Medtech Innovation Briefing (MIB) on Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions

  5. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

  6. The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)

    NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers

  7. Active B12 assay for diagnosing vitamin B12 deficiency (MIB40)

    NICE has developed a medtech innovation briefing (MIB) on the Active-B12 assay for diagnosing vitamin B12 deficiency

  8. Head injury: assessment and early management (NG232)

    This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.

  9. Implantation of an opaque intraocular lens for intractable double vision (IPG293)

    Evidence-based recommendations on implantation of an opaque intraocular lens for intractable double vision. This involves replacing the clear lens of one eye with a non-transparent one to block out one of the double images.

  10. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued [GID-TA11259]

  11. Selumetinib for treating differentiated thyroid cancer [ID1079]

    Discontinued [GID-TA10207]

  12. Translaryngeal tracheostomy (IPG462)

    Evidence-based recommendations on translaryngeal tracheostomy (TLT). This involves passing a tube from inside the windpipe to outside the neck to aid breathing.

  13. Minimally invasive video‑assisted parathyroidectomy (IPG501)

    Evidence-based recommendations on minimally invasive video-assisted parathyroidectomy. This involves inserting surgical instruments through a small cut (keyhole surgery) to find and remove any abnormal glands.

  14. Diabetes: annual care processes (children) (IND48)

    This indicator covers the proportion of children and young people with diabetes who receive individual care processes in the past 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG66

  15. What is the clinical and cost effectiveness of a block and replace regimen compared with a titration regimen of antithyroid drugs for Graves' disease?

    applicable) Source guidance details Comes from guidance Thyroid disease: assessment and management Number NG145 Date issued